To find patients who may be eligible for the NCI-MATCH trial, several commercial and academic laboratories are permitted by the National Cancer Institute to identify and refer potentially eligible patients to the trial. These referrals are based upon each lab’s standard tumor gene tests ordered by physicians to guide clinical care for their patients.
The laboratory referral process applies to any cancer patient who gets tumor gene testing at one of the nearly 1100 hospitals and clinics participating in the trial. NCI-MATCH is open and enrolling patients at nearly 1100 cancer centers and community hospitals in every state, the District of Columbia, and Puerto Rico. For locations, visit the NCI website.
Following are the basic steps:
Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.
Name | Learn More | Contact |
Ashion Analytics, LLC
Joined 12/18/2019 |
Visit website | Inquire via email |
Caris Life Sciences®
Joined 06/23/2017 |
Visit website | Inquire via email |
CellNetix Pathology and Laboratories
Joined 02/13/2019 |
Visit website | Inquire via email |
Foundation Medicine, Inc.
Joined 05/11/2017 |
Visit website | Inquire via email |
GenPath (BioReference Laboratories, Inc.)
Joined 08/03/2018 |
Visit website | Inquire via email |
NeoGenomics Laboratories, Inc.
Joined 07/02/2018 |
Visit website | Inquire via email |
OmniSeq, Inc.
Joined 07/16/2018 |
Visit website | Inquire via email |
PathGroup (This site has temporarily suspended outreach to patients.) Joined 10/29/2018 |
Visit website | Inquire via email |
Quest Diagnostics Inc.
Joined 05/20/2019 |
Visit website | Inquire via email |
Strata Oncology, Inc.
Joined 08/03/2018 |
Visit website | Inquire via email |
Tempus Labs, Inc.
Joined 07/16/2018 |
Visit website | Inquire via email |
The Jackson Laboratory
Joined 01/10/2019 |
Visit website | Inquire via email |
Name | Joined |
Augusta University – Georgia Esoteric & Molecular Diagnostic Laboratory | 10/15/2018 |
Brigham and Women’s Hospital – Center for Advanced Molecular Diagnostics | 04/17/2019 |
Cedars-Sinai Medical Center – Molecular Pathology Laboratory | 02/13/2019 |
City of Hope National Medical Center – Clinical Molecular Diagnostics Laboratory | 11/02/2018 |
Columbia University – Laboratory of Personalized Genomic Medicine in the Department of Pathology and Cell Biology | 07/25/2018 |
Johns Hopkins Genomics | 01/29/2019 |
Massachusetts General Hospital – Center for Integrated Diagnostics | 07/25/2018 |
MD Anderson Cancer Center | 05/11/2017 |
Memorial Sloan Kettering Cancer Center | 08/03/2017 |
Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research | 04/16/2019 |
National Cancer Institute – Laboratory of Pathology | 07/03/2019 |
Stanford Health Care – Molecular Genetic Pathology Laboratory | 02/25/2019 |
University of Chicago – Clinical Genomics Laboratory (This site has temporarily suspended outreach to patients.) | 10/05/2018 |
University of Colorado – Colorado Molecular Correlates Laboratory | 11/19/2018 |
University of Michigan – Michigan Medicine Molecular Diagnostics Laboratory | 10/19/2018 |
University of Washington – Genetics and Solid Tumor Laboratory | 09/16/2019 |
Weill Cornell Medicine – Clinical Genomics Laboratory | 08/03/2018 |
Yale University – Yale Tumor Profiling Laboratory | 06/20/2018 |
Return to Top | Return to NCI-MATCH / EAY131 Home Page
© 2012-2020 ECOG-ACRIN Cancer Research Group. All rights reserved. | Disclaimer